HC Wainwright Issues Pessimistic Forecast for Oculis (NASDAQ:OCS) Stock Price
Oculis (NASDAQ:OCS – Get Free Report) had its price target decreased by equities researchers at HC Wainwright from $30.00 to $29.00 in a research report issued to clients and investors on ...
Chardan Capital Reaffirms Buy Rating for Oculis (NASDAQ:OCS)
Oculis (NASDAQ:OCS – Get Free Report)‘s stock had its “buy” rating restated by Chardan Capital in a note issued to investors on Thursday,Benzinga reports. They presently have a $28.00 price target on ...
ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label
ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) ...
Our children are rapidly losing their sight. What can be done?
Every morning – shortly after checking my phone and shortly before brushing my teeth – I pull down my lower eyelids in turn ...
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
Scientific publications and reach in the field have shown already that post-injury angiogenesis and vascular remodeling ...